{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000870","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.446723+00:00","generated_at":"2026-05-28T02:59:11.153165+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M","bullets":["FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.","FY2025 revenue guided >$485M, net income >$170M, Adj EBITDA >$220M; FY2026 revenue >$600M, net income >$230M.","PAS submitted to FDA for yield enhancement process that could increase IG yields ~20%; approval expected mid-2025.","Executed long-term high titer plasma supply contracts from ~250 collection centers (5x increase) to support ASCENIV growth.","Balance sheet: net cash surplus vs. $75M debt; expect >$1B annual revenue before 2030 with outsized earnings growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000870","json":"https://secwatch.observer/filing/0001140361-25-000870.json","markdown":"https://secwatch.observer/filing/0001140361-25-000870.md","text":"https://secwatch.observer/filing/0001140361-25-000870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000870/0001140361-25-000870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000870/ef20041448_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:59:11.153165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}